Ubiquitin-proteasome system alterations in a striatal cell model of Huntington's disease

Journal of Neuroscience Research

Volumn 85, Issue 8, 2007, Pages 1774-1788

  Hunter, Jesse M ^a   Lesort, Mathieu ^a   Johnson, Gail V W ^a,b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Huntingtin; Huntington's disease; Luciferase reporter assay; Proteasome; Proteolysis; Ubiquitin

Indexed keywords

3 NITROPROPIONIC ACID; CASPASE; CHYMOTRYPSIN; FIREFLY LUCIFERASE; HUNTINGTIN; PROTEASOME; PROTEASOME INHIBITOR; TRYPSIN; UBIQUITIN;

ANIMAL CELL; ARTICLE; CELL CULTURE; CONTROLLED STUDY; CORPUS STRIATUM; ENZYME ASSAY; FIREFLY; HUNTINGTON CHOREA; NONHUMAN; PRIORITY JOURNAL; UBIQUITINATION;

CELL LINE; CORPUS STRIATUM; FLUORESCENT DYES; GENES, REPORTER; HUMANS; HUNTINGTON DISEASE; LUCIFERASES, FIREFLY; MUTATION; NERVE TISSUE PROTEINS; NITRO COMPOUNDS; NUCLEAR PROTEINS; OLIGOPEPTIDES; PROPIONIC ACIDS; PROTEASOME ENDOPEPTIDASE COMPLEX; SUCCINATE DEHYDROGENASE; UBIQUITIN;

EID: 34249802905     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.21287     Document Type: Article

References (96)

1. Arendt CS, Hochstrasser M. 1997. Identification of the yeast 20S proteasome catalytic centers and subunit interactions required for active-site formation. Proc Natl Acad Sci U S A 94:7156-7161.
2. Arrasate M, Mitra S, Schweitzer ES, Segal MR, Finkbeiner S. 2004. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 431:805-810.
3. Arribas J, Castano JG. 1990. Kinetic studies of the differential effect of detergents on the peptidase activities of the multicatalytic proteinase from rat liver. J Biol Chem 265:13969-13973.
4. Aylward EH, Li Q, Stine OC, Ranen N, Sherr M, Barta PE, Bylsma FW, Pearlson GD, Ross CA. 1997. Longitudinal change in basal ganglia volume in patients with Huntington's disease. Neurology 48:394-399.
5. Bao W, Thullberg M, Zhang H, Onischenko A, Stromblad S. 2002. Cell attachment to the extracellular matrix induces proteasomal degradation of p21(CIP1) via Cdc42/Rac1 signaling. Mol Cell Biol 22:4587-4597.
6. Bence NF, Sampat RM, Kopito RR. 2001. Impairment of the ubiquitin-proteasome system by protein aggregation. Science 292:1552-1555.
7. Bett JS, Goellner GM, Woodman B, Pratt G, Rechsteiner M, Bates GP. 2006. Proteasome impairment does not contribute to pathogenesis in R6/2 Huntington's disease mice: exclusion of proteasome activator REGgamma as a therapeutic target. Hum Mol Genet 15:33-44.
8. Bowman AB, Yoo SY, Dantuma NP, Zoghbi HY. 2005. Neuronal dysfunction in a polyglutamine disease model occurs in the absence of ubiquitin-proteasome system impairment and inversely correlates with the degree of nuclear inclusion formation. Hum Mol Genet 14:679-691.
9. Braun BC, Glickman M, Kraft R, Dahlmann B, Kloetzel PM, Finley D, Schmidt M. 1999. The base of the proteasome regulatory particle exhibits chaperone-like activity. Nat Cell Biol 1:221-226.
10. Chen X, Chi Y, Bloecher A, Aebersold R, Clurman BE, Roberts JM. 2004. N-acetylation and ubiquitin-independent proteasomal degradation of p21(Cip1). Mol Cell 16:839-847.
11. Cooper JK, Schilling G, Peters MF, Herring WJ, Sharp AH, Kaminsky Z, Masone J, Khan FA, Delanoy M, Borchelt DR, Dawson VL, Dawson TM, Ross CA. 1998. Truncated N-terminal fragments of huntingtin with expanded glutamine repeats form nuclear and cytoplasmic aggregates in cell culture. Hum Mol Genet 7:783-790.
12. Davies KJ. 2001. Degradation of oxidized proteins by the 20S proteasome. Biochimie 83:301-310.
13. Davies SW, Turmaine M, Cozens BA, DiFiglia M, Sharp AH, Ross CA, Scherzinger E, Wanker EE, Mangiarini L, Bates GP. 1997. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90:537-548.
14. Deveraux Q, Ustrell V, Pickart C, Rechsteiner M. 1994. A 26 S protease subunit that binds ubiquitin conjugates. J Biol Chem 269:7059-7061.
15. Diaz-Hernandez M, Hernandez F, Martin-Aparicio E, Gomez-Ramos P, Moran MA, Castano JG, Ferrer I, Avila J, Lucas JJ. 2003. Neuronal induction of the immunoproteasome in Huntington's disease. J Neurosci 23:11653-11661.
16. Diaz-Hernandez M, Martin-Aparicio E, Avila J, Hernandez F, Lucas JJ. 2004a. Enhanced induction of the immunoproteasome by interferon gamma in neurons expressing mutant Huntingtin. Neurotox Res 6:463-468.
17. Diaz-Hernandez M, Moreno-Herrero F, Gomez-Ramos P, Moran MA, Ferrer I, Baro AM, Avila J, Hernandez F, Lucas JJ. 2004b. Biochemical, ultrastructural, and reversibility studies on huntingtin filaments isolated from mouse and human brain. J Neurosci 24:9361-9371.
18. DiFiglia M, Sapp E, Chase KO, Davies SW, Bates GP, Vonsattel JP, Aronin N. 1997. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277:1990-1993.
19. Djaballah H, Rivett AJ. 1992. Peptidylglutamyl-peptide hydrolase activity of the multicatalytic proteinase complex: evidence for a new high-affinity site, analysis of cooperative kinetics, and the effect of manganese ions. Biochemistry 31:4133-4141.
20. Elofsson M, Splittgerber U, Myung J, Mohan R, Crews CM. 1999. Towards subunit-specific proteasome inhibitors: synthesis and evaluation of peptide alpha',beta'-epoxyketones. Chem Biol 6:811-822.
21. Gilon T, Chomsky O, Kulka RG. 1998. Degradation signals for ubiquitin system proteolysis in Saccharomyces cerevisiae. EMBO J 17:2759-2766.
22. Gines S, Seong IS, Fossale E, Ivanova E, Trettel F, Gusella JF, Wheeler VC, Persichetti F, MacDonald ME. 2003. Specific progressive cAMP reduction implicates energy deficit in presymptomatic Huntington's disease knock-in mice. Hum Mol Genet 12:497-508.
23. Glickman MH, Ciechanover A. 2002. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 82:373-428.
24. Glickman MH, Rubin DM, Fried VA, Finley D. 1998. The regulatory particle of the Saccharomyces cerevisiae proteasome. Mol Cell Biol 18:3149-3162.
25. Goellner GM, Rechsteiner M. 2003. Are Huntington's and polyglutamine-based ataxias proteasome storage diseases? Int J Biochem Cell Biol 35:562-571.
26. Groll M, Bajorek M, Kohler A, Moroder L, Rubin DM, Huber R, Glickman MH, Finley D. 2000. A gated channel into the proteasome core particle. Nat Struct Biol 7:1062-1067.
27. Groll M, Ditzel L, Lowe J, Stock D, Bochtler M, Bartunik HD, Huber R. 1997. Structure of 20S proteasome from yeast at 2.4 A resolution. Nature 386:463-471.
28. Groll M, Huber R. 2004. Inhibitors of the eukaryotic 20S proteasome core particle: a structural approach. Biochim Biophys Acta 1695:33-44.
29. Gutekunst CA, Li SH, Yi H, Mulroy JS, Kuemmerle S, Jones R, Rye D, Ferrante RJ, Hersch SM, Li XJ. 1999. Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. J Neurosci 19:2522-2534.
30. Heinemeyer W, Fischer M, Krimmer T, Stachon U, Wolf DH. 1997. The active sites of the eukaryotic 20 S proteasome and their involvement in subunit precursor processing. J Biol Chem 272:25200-25209.
31. Heinemeyer W, Ramos PC, Dohmen RJ. 2004. The ultimate nano scale mincer: assembly, structure and active sites of the 20S proteasome core. Cell Mol Life Sci 61:1562-1578.
32. Holmberg CI, Staniszewski KE, Mensah KN, Matouschek A, Morimoto RI. 2004. Inefficient degradation of truncated polyglutamine proteins by the proteasome. EMBO J 23:4307-4318.
33. Hoyt MA, Coffino P. 2004. Ubiquitin-free routes into the proteasome. Cell Mol Life Sci 61:1596-1600.
34. Hunter JM, Crouse AB, Lesort M, Johnson GV, Detloff PJ. 2005. Verification of somatic CAG repeat expansion by pre-PCR fractionation. J Neurosci Methods 144:11-17.
35. Jana NR, Tanaka M, Wang G, Nukina N. 2000. Polyglutamine length-dependent interaction of Hsp40 and Hsp70 family chaperones with truncated N-terminal huntingtin: their role in suppression of aggregation and cellular toxicity. Hum Mol Genet 9:2009-2018.
36. Jana NR, Zemskov EA, Wang G, Nukina N. 2001. Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release. Hum Mol Genet 10:1049-1059.
37. Johnson ES, Battel B, Seufert W, Varshavsky A. 1992. Ubiquitin as a degradation signal. EMBO J 11:497-505.
38. Johnston JA, Madura K. 2004. Rings, chains and ladders: ubiquitin goes to work in the neuron. Prog Neurobiol 73:227-257.
39. Kalchman MA, Graham RK, Xia G, Koide HB, Hodgson JG, Graham KC, Goldberg YP, Gietz RD, Pickart CM, Hayden MR. 1996. Huntingtin is ubiquitinated and interacts with a specific ubiquitin-conjugating enzyme. J Biol Chem 271:19385-19394.
40. Kaytor MD, Wilkinson KD, Warren ST. 2004. Modulating huntingtin half-life alters polyglutamine-dependent aggregate formation and cell toxicity. J Neurochem 89:962-973.
41. Kennedy L, Evans E, Chen CM, Craven L, Detloff PJ, Ennis M, Shelbourne PF. 2003. Dramatic tissue-specific mutation length increases are an early molecular event in Huntington disease pathogenesis. Hum Mol Genet 12:3359-3367.
42. Kennedy L, Shelbourne PF. 2000. Dramatic mutation instability in HD mouse striatum: does polyglutamine load contribute to cell-specific vulnerability in Huntington's disease? Hum Mol Genet 9:2539-2544.
43. Kisselev AF, Garcia-Calvo M, Overkleeft HS, Peterson E, Pennington MW, Ploegh HL, Thornberry NA, Goldberg AL. 2003. The caspase-like sites of proteasomes, their substrate specificity, new inhibitors and substrates, and allosteric interactions with the trypsin-like sites. J Biol Chem 278:35869-35877.
44. Kisselev AF, Songyang Z, Goldberg AL. 2000. Why does threonine, and not serine, function as the active site nucleophile in proteasomes? J Biol Chem 275:14831-14837.
45. Kohler A, Cascio P, Leggett DS, Woo KM, Goldberg AL, Finley D. 2001. The axial channel of the proteasome core particle is gated by the Rpt2 ATPase and controls both substrate entry and product release. Mol Cell 7:1143-1152.
46. Landles C, Bates GP. 2004. Huntingtin and the molecular pathogenesis of Huntington's disease. Fourth in molecular medicine review series. EMBO Rep 5:958-963.
47. Lee CS, Tee LY, Warmke T, Vinjamoori A, Cai A, Fagan AM, Snider BJ. 2004. A proteasomal stress response: pre-treatment with proteasome inhibitors increases proteasome activity and reduces neuronal vulnerability to oxidative injury. J Neurochem 91:996-1006.
48. Li SH, Li XJ. 1998. Aggregation of N-terminal huntingtin is dependent on the length of its glutamine repeats. Hum Mol Genet 7:777-782.
49. Lin CH, Tallaksen-Greene S, Chien WM, Cearley JA, Jackson WS, Crouse AB, Ren S, Li XJ, Albin RL, Detloff PJ. 2001. Neurological abnormalities in a knock-in mouse model of Huntington's disease. Hum Mol Genet 10:137-144.
50. Link CD, Fonte V, Hiester B, Yerg J, Ferguson J, Csontos S, Silverman MA, Stein GH. 2006. Conversion of green fluorescent protein into a toxic, aggregation-prone protein by C-terminal addition of a short peptide. J Biol Chem 281:1808-1816.
51. Lowe J, Stock D, Jap B, Zwickl P, Baumeister W, Huber R. 1995. Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 A resolution. Science 268:533-539.
52. Luker GD, Pica CM, Song J, Luker KE, Piwnica-Worms D. 2003. Imaging 26S proteasome activity and inhibition in living mice. Nat Med 9:969-973.
53. Mao Z, Choo YS, Lesort M. 2006. Cystamine and cysteamine prevent 3-NP-induced mitochondrial depolarization of Huntington's disease knock-in striatal cells. Eur J Neurosci 23:1701-1710.
54. Martin-Aparicio E, Yamamoto A, Hernandez F, Hen R, Avila J, Lucas JJ. 2001. Proteasomal-dependent aggregate reversal and absence of cell death in a conditional mouse model of Huntington's disease. J Neurosci 21:8772-8781.
55. Martindale D, Hackam A, Wieczorek A, Ellerby L, Wellington C, McCutcheon K, Singaraja R, Kazemi-Esfarjani P, Devon R, Kim SU, Bredesen DE, Tufaro F, Hayden MR. 1998. Length of huntingtin and its polyglutamine tract influences localization and frequency of intracellular aggregates. Nat Genet 18:150-154.
56. Meng L, Mohan R, Kwok BH, Elofsson M, Sin N, Crews CM. 1999. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc Natl Acad Sci U S A 96:10403-10408.
57. Michalik A, Van Broeckhoven C. 2004. Proteasome degrades soluble expanded polyglutamine completely and efficiently. Neurobiol Dis 16:202-211.
58. Milakovic T, Johnson GV. 2005. Mitochondrial respiration and ATP production are significantly impaired in striatal cells expressing mutant huntingtin. J Biol Chem 280:30773-30782.
59. Orlowski M, Wilk S. 2000. Catalytic activities of the 20 S proteasome, a multicatalytic proteinase complex. Arch Biochem Biophys 383:1-16.
60. Orlowski M, Wilk S. 2003. Ubiquitin-independent proteolytic functions of the proteasome. Arch Biochem Biophys 415:1-5.
61. Perutz MF. 1995. Polar zippers: their role in human disease. Pharm Acta Helv 69:213-224.
62. Perutz MF, Johnson T, Suzuki M, Finch JT. 1994. Glutamine repeats as polar zippers: their possible role in inherited neurodegenerative diseases. Proc Natl Acad Sci U S A 91:5355-5358.
63. Rosas HD, Goodman J, Chen YI, Jenkins BG, Kennedy DN, Makris N, Patti M, Seidman LJ, Beal MF, Koroshetz WJ. 2001. Striatal volume loss in HD as measured by MRI and the influence of CAG repeat. Neurology 57:1025-1028.
64. Rosas HD, Koroshetz WJ, Chen YI, Skeuse C, Vangel M, Cudkowicz ME, Caplan K, Marek K, Seidman LJ, Makris N, Jenkins BG, Goldstein JM. 2003. Evidence for more widespread cerebral pathology in early HD: an MRI-based morphometric analysis. Neurology 60:1615-1620.
65. Rosas HD, Liu AK, Hersch S, Glessner M, Ferrante RJ, Salat DH, van der Kouwe A, Jenkins BG, Dale AM, Fischi B. 2002. Regional and progressive thinning of the cortical ribbon in Huntington's disease. Neurology 58:695-701.
66. Ruan Q, Lesort M, MacDonald ME, Johnson GV. 2004. Striatal cells from mutant huntingtin knock-in mice are selectively vulnerable to mitochondrial complex II inhibitor-induced cell death through a non-apoptotic pathway. Hum Mol Genet 13:669-681.
67. Saudou F, Finkbeiner S, Devys D, Greenberg ME. 1998. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 95:55-66.
68. Scherzinger E, Lurz R, Turmaine M, Mangiarini L, Hollenbach B, Hasenbank R, Bates GP, Davies SW, Lehrach H, Wanker EE. 1997. Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell 90:549-558.
69. Scherzinger E, Sittler A, Schweiger K, Heiser V, Lurz R, Hasenbank R, Bates GP, Lehrach H, Wanker EE. 1999. Self-assembly of polyglutamine-containing huntingtin fragments into amyloid-like fibrils: implications for Huntington's disease pathology. Proc Natl Acad Sci U S A 96:4604-4609.
70. Seeger M, Ferrell K, Dubiel W. 1997. The 26S proteasome: a dynamic structure. Mol Biol Rep 24:83-88.
71. Seemuller E, Lupas A, Stock D, Lowe J, Huber R, Baumeister W. 1995. Proteasome from Thermoplasma acidophilum: a threonine protease. Science 268:579-582.
72. Seo H, Sonntag KC, Isacson O. 2004. Generalized brain and skin proteasome inhibition in Huntington's disease. Ann Neurol 56:319-328.
73. Seong IS, Ivanova E, Lee JM, Choo YS, Fossale E, Anderson M, Gusella JF, Laramie JM, Myers RH, Lesort M, MacDonald ME. 2005. HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism. Hum Mol Genet 14:2871-2880.
74. Sheaff RJ, Singer JD, Swanger J, Smitherman M, Roberts JM, Clurman BE. 2000. Proteasomal turnover of p21Cip1 does not require p21Cip1 ubiquitination. Mol Cell 5:403-410.
75. Sieradzan KA, Mechan AO, Jones L, Wanker EE, Nukina N, Mann DM. 1999. Huntington's disease intranuclear inclusions contain truncated, ubiquitinated huntingtin protein. Exp Neurol 156:92-99.
76. Stack JH, Whitney M, Rodems SM, Pollok BA. 2000. A ubiquitin-based tagging system for controlled modulation of protein stability. Nat Biotechnol 18:1298-1302.
77. Stott K, Blackburn JM, Butler PJ, Perutz M. 1995. Incorporation of glutamine repeats makes protein oligomerize: implications for neurodegenerative diseases. Proc Natl Acad Sci U S A 92:6509-6513.
78. Tallaksen-Greene SJ, Crouse AB, Hunter JM, Detloff PJ, Albin RL. 2005. Neuronal intranuclear inclusions and neuropil aggregates in HdhCAG(150) knockin mice. Neuroscience 131:843-852.
79. Telenius H, Kremer B, Goldberg YP, Theilmann J, Andrew SE, Zeisler J, Adam S, Greenberg C, Ives EJ, Clarke LA, et al. 1994. Somatic and gonadal mosaicism of the Huntington disease gene CAG repeat in brain and sperm. Nat Genet 6:409-414.
80. The Huntington's Disease Collaborative Research Group. 1993. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 72:971-983.
81. Thrower JS, Hoffman L, Rechsteiner M, Pickart CM. 2000. Recognition of the polyubiquitin proteolytic signal. EMBO J 19:94-102.
82. Touitou R, Richardson J, Bose S, Nakanishi M, Rivett J, Allday MJ. 2001. A degradation signal located in the C-terminus of p21WAF1/CIP1 is a binding site for the C8 alpha-subunit of the 20S proteasome. EMBO J 20:2367-2375.
83. Trettel F, Rigamonti D, Hilditch-Maguire P, Wheeler VC, Sharp AH, Persichetti F, Cattaneo E, MacDonald ME. 2000. Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells. Hum Mol Genet 9:2799-2809.
84. Trottier Y, Biancalana V, Mandel JL. 1994. Instability of CAG repeats in Huntington's disease: relation to parental transmission and age of onset. J Med Genet 31:377-382.
85. Valera AG, Diaz-Hernandez M, Hernandez F, Ortega Z, Lucas JJ. 2005. The ubiquitin-proteasome system in Huntington's disease. Neuroscientist 11:583-594.
86. Varshavsky A. 1996. The N-end rule: functions, mysteries, uses. Proc Natl Acad Sci U S A 93:12142-12149.
87. Varshavsky A. 1997. The ubiquitin system. Trends Biochem Sci 22:383-387.
88. Venkatraman P, Wetzel R, Tanaka M, Nukina N, Goldberg AL. 2004. Eukaryotic proteasomes cannot digest polyglutamine sequences and release them during degradation of polyglutamine-containing proteins. Mol Cell 14:95-104.
89. Wacker JL, Zareie MH, Fong H, Sarikaya M, Muchowski PJ. 2004. Hsp70 and Hsp40 attenuate formation of spherical and annular polyglutamine oligomers by partitioning monomer. Nat Struct Mol Biol 11:1215-1222.
90. Waelter S, Boeddrich A, Lurz R, Scherzinger E, Lueder G, Lehrach H, Wanker EE. 2001. Accumulation of mutant huntingtin fragments in aggresome-like inclusion bodies as a result of insufficient protein degradation. Mol Biol Cell 12:1393-1407.
91. Wilson SM, Bhattacharyya B, Rachel RA, Coppola V, Tessarollo L, Householder DB, Fletcher CF, Miller RJ, Copeland NG, Jenkins NA. 2002. Synaptic defects in ataxia mice result from a mutation in Usp14, encoding a ubiquitin-specific protease. Nat Genet 32:420-425.
92. Wyttenbach A. 2004. Role of heat shock proteins during polyglutamine neurodegeneration: mechanisms and hypothesis. J Mol Neurosci 23:69-96.
93. Wyttenbach A, Carmichael J, Swartz J, Furlong RA, Narain Y, Rankin J, Rubinsztein DC. 2000. Effects of heat shock, heat shock protein 40 (HDJ-2), and proteasome inhibition on protein aggregation in cellular models of Huntington's disease. Proc Natl Acad Sci U S A 97:2898-2903.
94. Wyttenbach A, Sauvageot O, Carmichael J, Diaz-Latoud C, Arrigo AP, Rubinsztein DC. 2002. Heat shock protein 27 prevents cellular polyglutamine toxicity and suppresses the increase of reactive oxygen species caused by huntingtin. Hum Mol Genet 11:1137-1151.
95. Yamamoto A, Lucas JJ, Hen R. 2000. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell 101:57-66.
96. Young P, Deveraux Q, Beal RE, Pickart CM, Rechsteiner M. 1998. Characterization of two polyubiquitin binding sites in the 26 S protease subunit 5a. J Biol Chem 273:5461-5467.